Evidence map›Paper›PMID 23734089›Full record

ArticleMolecular vision2013

Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes.

Rajendra S Kadam, Jason Williams, Puneet Tyagi, Henry F Edelhauser, Uday B Kompella

RetractedOpen access · greenAbstract readComparative StudyRetracted Publication
In one paragraph

Article in Molecular vision, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Nanomedicine in the application of uveal melanoma.International journal of ophthalmology · 2016
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rajendra S KadamNanomedicine and Drug Delivery Laboratory, Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Jason Williams
Puneet Tyagi
Henry F Edelhauser
Uday B Kompella
University of Colorado Anschutz Medical Campus · US

Funding

Transscleral Drug Delivery for Retinal DisordersR24EY017045 · NEI · EMORY UNIVERSITY · PI EDELHAUSER, HENRY FRANCIS · 2006 to 2010
$6.9M
Transcleral Therapeutics in Diabetic RetinopathyR01EY018940 · NEI · UNIVERSITY OF COLORADO DENVER · PI KOMPELLA, UDAY B · 2010 to 2014
$2.4M
Influence of eye pigmentation and diabetes on retinal drug deliveryR01EY017533 · NEI · UNIVERSITY OF COLORADO DENVER · PI KOMPELLA, UDAY B · 2009 to 2010
$806k
NEI NIH HHS R01 EY017533NEI NIH HHS R01EY017533NEI NIH HHS R01 EY018940NEI NIH HHS R01EY018940NEI NIH HHS R24 EY017045NEI NIH HHS R24EY017045
6 · The paper itself

Abstract

purposeFirst, to determine the influence of drug lipophilicity (using eight beta-blockers) and molecular weight (using 4 kDa and 40 kDa fluoroscein isothiocyanate [FITC]-dextrans) on suprachoroidal delivery to the posterior segment of the eye by using a rabbit ex vivo eye model. Second, to determine whether drug distribution differs between the dosed and undosed side of the eye following suprachoroidal delivery. Third, to compare the suprachoroidal delivery of sodium fluorescein (NaF) with the intracameral and intravitreal routes by using noninvasive fluorophotometry.

methodsUsing a small hypodermic 26G needle (3/8") with a short bevel (250 µm), location of the suprachoroidal injection in an ex vivo New Zealand white rabbit eye model was confirmed with India ink. Ocular tissue distribution of NaF (25 µl of 1.5 µg/ml) at 37 °C was monitored noninvasively using the Fluorotron Master(TM) at 0, 1, and 3 h following suprachoroidal, intravitreal, or intracameral injections in ex vivo rabbit eyes. For assessing the influence of lipophilicity and molecular size, 25 µl of a mixture of eight beta-blockers (250 µg/ml each) or FITC-dextran (4 kDa and 40 kDa, 30 mg/ml) was injected into the suprachoroidal space of excised rabbit eyes and incubated at 37 °C. Eyes were incubated for 1 and 3 h, and frozen at the end of incubation. Ocular tissues were isolated in frozen condition. Beta-blocker and FITC-dextran levels in excised ocular tissue were measured by liquid chromatography-tandem mass spectrometry and spectrofluorometry, respectively.

resultsHistological sections of India ink-injected albino rabbit eye showed the localization of dye as a black line in the suprachoroidal space. Suprachoroidal injection of NaF showed signal localization to the choroid and retina at 1 and 3 h post injection when compared with intravitreal and intracameral injections. Drug delivery to the vitreous after suprachoroidal injection decreased with an increase in solute lipophilicity and molecular weight. With an increase in drug lipophilicity, drug levels in the choroid-retinal pigment epithelium (RPE) and retina generally increased with some exceptions. Beta-blockers and FITC-dextrans were localized more to the dosed side when compared to the opposite side of the sclera, choroid-RPE, retina, and vitreous. These differences were greater for FITC-dextrans as compared to the beta-blockers.

conclusionsThe suprachoroidal route of injection allows localized delivery to the choroid-RPE and retina for small as well as large molecules. Suprachoroidal drug delivery to the vitreous declines with an increase in drug lipophilicity and molecular weight. Drug delivery differs between the dosed and opposite sides following suprachoroidal injection, at least up to 3 h.

Indexed as

Drug Delivery SystemsAdrenergic beta-AntagonistsAnimalsCarbonChoroidDextransDrug Administration RoutesFluoresceinFluorescein-5-isothiocyanateFluorophotometryIntravitreal InjectionsIn Vitro TechniquesModels, AnimalRabbitsRetinaTissue DistributionAdrenergic beta-AntagonistsCarbonchinese inkDextransFluoresceinFluorescein-5-isothiocyanatefluorescein isothiocyanate dextran

Identifiers

PMID23734089
PMCPMC3669536
OpenAlexW2104086573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.